NALTREXONE (low dose)
Clinical Indication
Mast Cell Activation Syndrome (MCAS)
Date of classification
July 2020
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.